Kanwal P Raghav
University of Texas MD Anderson Cancer Center LAO · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kanwal P Raghav as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07551596 · Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat TrialNational Cancer Institute (NCI) · recruiting · Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8 · principal investigator
- Ph1NCT04704661 · Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialNational Cancer Institute (NCI) · active not recruiting · Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma · principal investigator
- Ph2NCT03108131 · Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsM.D. Anderson Cancer Center · completed · Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion · principal investigator
- Ph2NCT03074513 · Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsM.D. Anderson Cancer Center · active not recruiting · Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A technological approach for performance status assessment in advanced cancer patientsR01CA243554 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2024 · $546,557 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026Named on NCT07551596, NCT04704661
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:26 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol · 2019457 citationsRCR 15.6
- Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).J Clin Oncol · 2021295 citationsRCR 15.5
- Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.J Clin Oncol · 2023181 citationsRCR 14.4
- Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.Br J Cancer · 201946 citationsRCR 1.7
- Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.JAMA Netw Open · 202341 citationsRCR 4.8
- Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer.Cancer Cell · 202524 citationsRCR 5.0
- Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial.Nat Med · 202523 citationsRCR 4.2
- 11 citationsRCR 1.7
- Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma.Cancer Res Commun · 20249 citationsRCR 1.5